[go: up one dir, main page]

CN110478430A - Application of the civil and military soup of a thousand pieces of gold in the drug that retinal pigment epithelium ARPE-19 fibrosis is intervened in preparation - Google Patents

Application of the civil and military soup of a thousand pieces of gold in the drug that retinal pigment epithelium ARPE-19 fibrosis is intervened in preparation Download PDF

Info

Publication number
CN110478430A
CN110478430A CN201910942490.XA CN201910942490A CN110478430A CN 110478430 A CN110478430 A CN 110478430A CN 201910942490 A CN201910942490 A CN 201910942490A CN 110478430 A CN110478430 A CN 110478430A
Authority
CN
China
Prior art keywords
arpe
soup
civil
military
gold
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910942490.XA
Other languages
Chinese (zh)
Inventor
郭建鹏
李日晖
李岳琦
金成山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yanbian University
Original Assignee
Yanbian University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yanbian University filed Critical Yanbian University
Priority to CN201910942490.XA priority Critical patent/CN110478430A/en
Publication of CN110478430A publication Critical patent/CN110478430A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/23Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232Angelica
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/23Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236Ligusticum (licorice-root)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/34Campanulaceae (Bellflower family)
    • A61K36/346Platycodon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/488Pueraria (kudzu)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539Scutellaria (skullcap)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/57Magnoliaceae (Magnolia family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/71Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/79Schisandraceae (Schisandra family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/894Dioscoreaceae (Yam family)
    • A61K36/8945Dioscorea, e.g. yam, Chinese yam or water yam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/896Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8968Ophiopogon (Lilyturf)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to application of the civil and military soup of a thousand pieces of gold in the drug that retinal pigment epithelium ARPE-19 fibrosis is intervened in preparation, belong to technical field of traditional Chinese medicines.The present invention provides application of the civil and military soup of a thousand pieces of gold in the drug that retinal pigment epithelium ARPE-19 fibrosis is intervened in preparation.Compared with model group, the civil and military soup of a thousand pieces of gold can raise E-cad protein expression with dosage-dependent manner, lower α-SMA and COL-I protein expression.

Description

千金文武汤在制备干预视网膜色素上皮细胞ARPE-19纤维化 的药物中的应用Qianjin Wenwu Decoction Intervenes in the Preparation of ARPE-19 Fibrosis in Retinal Pigment Epithelial Cells application in medicine

技术领域technical field

本发明涉及中药技术领域,具体涉及千金文武汤在制备干预视网膜色素上皮细胞ARPE-19纤维化的药物中的应用。The invention relates to the technical field of traditional Chinese medicines, in particular to the application of Qianjin Wenwu Decoction in the preparation of medicines for intervening ARPE-19 fibrosis of retinal pigment epithelial cells.

背景技术Background technique

千金文武汤(Qian-Jin-Wen-Wu Decoction,QWD)出自朝医学著作《东医四象新编》,由葛根、黄芩、藁本、山药、五味子、桔梗、升麻、白芷和麦冬九味药组成,主治太阴人消渴肾病,临床用于糖尿病及其并发症疗效显著。前期药理学研究表明,其对视黄醇结合蛋白的表达有抑制作用,可减缓或抑制糖尿病肾病(Diabetic kidney disease,DKD)大鼠视网膜病变发病率和病程,但其具体作用机理有待探究。Qian-Jin-Wen-Wu Decoction (QWD) comes from the Korean medical book "The New Edition of the Four Elephants of Eastern Medicine". Composed of flavored medicines, it is mainly used for the treatment of diabetes and kidney disease in Taiyin people, and it has a remarkable curative effect when used clinically for diabetes and its complications. Previous pharmacological studies have shown that it has an inhibitory effect on the expression of retinol-binding protein, and can slow down or inhibit the incidence and course of retinopathy in diabetic kidney disease (DKD) rats, but its specific mechanism remains to be explored.

发明内容Contents of the invention

本发明的目的在于提供千金文武汤在制备干预视网膜色素上皮细胞ARPE-19纤维化的药物中的应用。The purpose of the present invention is to provide the application of Qianjin Wenwu Decoction in the preparation of medicine for intervening ARPE-19 fibrosis of retinal pigment epithelial cells.

本发明提供了千金文武汤在制备干预视网膜色素上皮细胞ARPE-19纤维化的药物中的应用。The invention provides the application of Qianjin Wenwu Decoction in the preparation of a drug for intervening ARPE-19 fibrosis of retinal pigment epithelial cells.

本发明还提供了千金文武汤在制备抑制视网膜色素上皮细胞ARPE-19纤维化的药物中的应用。The present invention also provides the application of Qianjin Wenwu Decoction in the preparation of medicine for inhibiting ARPE-19 fibrosis of retinal pigment epithelial cells.

本发明还提供了千金文武汤在制备抑制高糖诱导视网膜色素上皮细胞ARPE-19纤维化的药物中的应用。The present invention also provides the application of Qianjin Wenwu Decoction in the preparation of medicine for inhibiting ARPE-19 fibrosis of retinal pigment epithelial cells induced by high glucose.

优选的是,所述千金文武汤的制备用原料由葛根、黄芩、藁本、山药、五味子、桔梗、升麻、白芷和麦冬组成。Preferably, the raw materials for the preparation of Qianjin Wenwu Decoction consist of kudzu root, scutellaria baicalensis, ligusticum edulis, Chinese yam, schisandra chinensis, bellflower, cohosh, angelica dahurica and Radix Ophiopogon japonicus.

优选的是,所述千金文武汤的制备用原料由葛根10g、黄芩10g、藁本10g、山药10g、五味子5g、桔梗5g、升麻5g、白芷5g和麦冬5g组成。Preferably, the raw materials for the preparation of Qianjin Wenwu Decoction are composed of 10 g of kudzu root, 10 g of scutellaria baicalensis, 10 g of Ligusticum edulis, 10 g of Chinese yam, 5 g of schisandra chinensis, 5 g of bellflower, 5 g of Cimicifuga, 5 g of Angelica dahurica and 5 g of Ophiopogon japonicus.

本发明提供了千金文武汤在制备干预视网膜色素上皮细胞ARPE-19纤维化的药物中的应用。本发明朝医方“千金文武汤”能够干预高糖诱导视网膜色素上皮细胞ARPE-19的纤维化进程。试验结果表明,高糖诱导后,与正常组比较,模型组细胞明显变长呈纺锤形,且E-cad蛋白表达下调,α-SMA和COL-I蛋白表达上调;给药(千金文武汤)后,与模型组比较,以剂量依赖性方式上调E-cad蛋白表达,下调α-SMA和COL-I蛋白表达。The invention provides the application of Qianjin Wenwu Decoction in the preparation of a drug for intervening ARPE-19 fibrosis of retinal pigment epithelial cells. The Korean medical prescription "Qianjin Wenwu Decoction" of the present invention can interfere with the fibrosis process of ARPE-19 induced by high glucose. The test results showed that after high glucose induction, compared with the normal group, the cells in the model group were significantly longer and spindle-shaped, and the expression of E-cad protein was down-regulated, and the expression of α-SMA and COL-I proteins were up-regulated; administration (Qianjin Wenwu Decoction) Afterwards, compared with the model group, the protein expression of E-cad was up-regulated in a dose-dependent manner, and the protein expression of α-SMA and COL-I was down-regulated.

附图说明Description of drawings

图1为本发明提供的不同浓度葡萄糖无血清培养基的细胞形态学观察结果图;Fig. 1 is the cell morphology observation result figure of different concentrations of glucose serum-free medium provided by the present invention;

图2为本发明提供的MTT实验检测千金文武汤对ARPE-19细胞毒性影响结果图;Fig. 2 is the MTT experiment provided by the present invention to detect Qianjin Wenwu decoction to ARPE-19 cytotoxic effect result figure;

图3为本发明提供的ARPE-19细胞被给予药物后细胞E-cad、α-SMA和COL-I蛋白表达免疫印迹图;Fig. 3 is the western blot of E-cad, α-SMA and COL-I protein expression in ARPE-19 cells provided by the present invention after being given drugs;

图4为本发明提供的ARPE-19细胞被给予药物后细胞E-cad、α-SMA和COL-I的蛋白表达柱状图。Fig. 4 is a histogram of protein expression of E-cad, α-SMA and COL-I in ARPE-19 cells provided by the present invention after being given drugs.

具体实施方式Detailed ways

本发明提供了千金文武汤在制备干预视网膜色素上皮细胞ARPE-19纤维化的药物中的应用。本发明所述千金文武汤为朝医方“千金文武汤”,在本发明中,所述千金文武汤的制备用原料由葛根、黄芩、藁本、山药、五味子、桔梗、升麻、白芷和麦冬组成;更优选的,所述千金文武汤的制备用原料由葛根10g、黄芩10g、藁本10g、山药10g、五味子5g、桔梗5g、升麻5g、白芷5g和麦冬5g组成。本发明对所述千金文武汤的来源没有特殊限定。具体的,本发明所述千金文武汤的制备优选包括:将原料的组合物分别经10倍量和8倍量30%乙醇两次提取混合后,浓缩至料液比1:1;再以0.05g.mL-1为上样浓度,用大孔吸附树脂(MAR)进行吸附;最后将纯化后的药液再次浓缩至料液比1:1,进行冷冻干燥后,得到千金文武汤。The invention provides the application of Qianjin Wenwu Decoction in the preparation of a drug for intervening ARPE-19 fibrosis of retinal pigment epithelial cells. The Qianjin Wenwu Decoction of the present invention is "Qianjin Wenwu Decoction" of the Korean medical prescription. In the present invention, the raw materials for the preparation of the Qianjin Wenwu Decoction are Pueraria lobata, Scutellaria baicalensis, Ligusticum edulis, Chinese yam, Schisandra chinensis, platycodon grandiflorum, Cimicifuga, Angelica dahurica and More preferably, the raw materials for the preparation of Qianjin Wenwu Decoction are composed of Pueraria 10g, Scutellaria baicalensis 10g, Ligusticum edodes 10g, Chinese yam 10g, Schisandra 5g, Platycodon grandiflorum 5g, Cimicifuga 5g, Angelica dahurica 5g and Ophiopogon japonicus 5g. The present invention has no special limitation on the source of Qianjin Wenwu Decoction. Specifically, the preparation of Qianjin Wenwu Decoction of the present invention preferably includes: extracting and mixing the composition of raw materials twice with 10 times and 8 times of 30% ethanol respectively, then concentrating to a solid-liquid ratio of 1:1; g.mL -1 is the concentration of the sample, and it is adsorbed by macroporous adsorbent resin (MAR); finally, the purified medicinal solution is concentrated again to a solid-liquid ratio of 1:1, and freeze-dried to obtain Qianjin Wenwu Decoction.

本发明还提供了千金文武汤在制备抑制视网膜色素上皮细胞ARPE-19纤维化的药物中的应用。The present invention also provides the application of Qianjin Wenwu Decoction in the preparation of medicine for inhibiting ARPE-19 fibrosis of retinal pigment epithelial cells.

本发明还提供了千金文武汤在制备抑制高糖诱导视网膜色素上皮细胞ARPE-19纤维化的药物中的应用。高糖诱导后,与正常组比较,模型组细胞明显变长呈纺锤形,且E-cad蛋白表达下调,α-SMA和COL-I蛋白表达上调;给药后,与模型组比较,以剂量依赖性方式上调E-cad蛋白表达,下调α-SMA和COL-I蛋白表达。The present invention also provides the application of Qianjin Wenwu Decoction in the preparation of medicine for inhibiting ARPE-19 fibrosis of retinal pigment epithelial cells induced by high glucose. After high glucose induction, compared with the normal group, the cells in the model group were significantly longer and spindle-shaped, and the expression of E-cad protein was down-regulated, and the expression of α-SMA and COL-I proteins were up-regulated; after administration, compared with the model group, the dose E-cad protein expression was up-regulated, and α-SMA and COL-I protein expression were down-regulated in a dependent manner.

下面结合具体实施例对本发明所述的千金文武汤在制备干预视网膜色素上皮细胞ARPE-19纤维化的药物中的应用做进一步详细的介绍,本发明的技术方案包括但不限于以下实施例。The application of Qianjin Wenwu Decoction of the present invention in the preparation of drugs for intervening ARPE-19 fibrosis of retinal pigment epithelial cells will be further described in detail below in conjunction with specific examples. The technical solutions of the present invention include but are not limited to the following examples.

实施例1Example 1

材料与仪器如表1和表2所示。Materials and instruments are shown in Table 1 and Table 2.

表1药材与试剂Table 1 Medicinal materials and reagents

表2主要仪器与设备Table 2 Main instruments and equipment

细胞培养cell culture

1、培养基的配置1. Configuration of culture medium

取胎牛血清,在55℃下灭活。将DMEM在37℃水浴条件下加热。配置含10%FBS的DMEM培养基。Fetal bovine serum was taken and inactivated at 55°C. Heat DMEM in a 37°C water bath. Prepare DMEM medium containing 10% FBS.

2、细胞复苏2. Cell Recovery

把已经配制完成的培养基放入37℃的水浴锅中加热,把人视网膜色素上皮ARPE-19细胞从-80℃冰箱中取出,放置于37℃的水浴锅中融化待用。在通风设备、照明设备良好的超净台中,用75%的酒精擦拭试验台,点燃酒精灯,进行培养基的瓶口灭菌,使用移液枪吸出5ml培养基,将其放置至15ml试管中,使用移液枪吸取细胞冻存液转移至试管中并离心3min(1000r·min-1)用吸引器吸出离心后的上清液,取适量的培养基吹打细胞直至分布均匀,最后转移至培养皿中,加入10ml培养基。将培养皿放入37℃,5%浓度的CO2培养箱中,培育48h。Heat the prepared medium in a 37°C water bath, take out the human retinal pigment epithelial ARPE-19 cells from the -80°C refrigerator, and place them in a 37°C water bath to melt for use. In an ultra-clean bench with good ventilation and lighting equipment, wipe the test bench with 75% alcohol, light the alcohol lamp, sterilize the bottle mouth of the medium, use a pipette gun to suck out 5ml of the medium, and place it into a 15ml test tube , use a pipette gun to transfer the frozen cell liquid to a test tube and centrifuge for 3 minutes (1000r·min -1 ). Use an aspirator to suck out the centrifuged supernatant, take an appropriate amount of medium and blow the cells until they are evenly distributed, and finally transfer to the culture medium. Into the dish, add 10ml medium. Put the culture dish into a 37°C, 5% CO 2 incubator and incubate for 48h.

3、细胞传代3. Cell passage

先将DMEM培养基与胰蛋白酶从冰箱中取出,在水浴锅中预热至37℃。从培养箱里将已经长满ARPE-19细胞的培养皿取出,用显微镜观察其细胞数量与细胞形态是否达到铺满培养皿底部80%要求。将达到要求的培养皿转移至75%擦拭过的通风照明良好的超净台,用吸引器抽走培养皿中上层的培养基,然后用培养基冲洗培养皿,洗去漂浮的死细胞。取3ml胰蛋白酶于培养皿中,上下左右均匀摇晃约1min使细胞与胰蛋白酶充分接触,将培养皿放置于培养箱中孵育,计时3min后取出。取出培养箱中的培养皿,加入培养基。拿出两个全新的培养基,用记号笔标注为ARPE-19细胞记录实验日期与实验者姓名,移入适量预先配好的培养基。取出培养箱中的培养皿,拍打使细胞滑落,在灯光下观察细胞是否呈流动状态,使用光学显微镜观察细胞分散情况,然后转移至试管中。将盛有细胞的试管放入高速离心机中3min(1000r·min-1),到时间后取出。用吸引器吸走上层清液,用移液枪加入培养基,将底部的细胞吹起,上下三十次。将吹打之后完全的细胞转移至新培养皿,然后进行十字摇摆,放置培养箱中培育。37℃,5%CO2中培育48h。First take the DMEM medium and trypsin out of the refrigerator, and preheat to 37°C in a water bath. Take out the culture dish that has been overgrown with ARPE-19 cells from the incubator, and use a microscope to observe whether the number of cells and the cell shape meet the requirement of covering 80% of the bottom of the culture dish. Transfer the petri dish that meets the requirements to a well-ventilated and well-lit ultra-clean bench that has been wiped by 75%, use an aspirator to suck away the medium in the upper layer of the petri dish, and then rinse the petri dish with the medium to wash away floating dead cells. Take 3ml of trypsin in a petri dish, shake evenly up and down, left and right for about 1 min to fully contact the cells with trypsin, place the petri dish in an incubator for incubation, and take it out after timing for 3 min. Remove the Petri dish from the incubator and add culture medium. Take out two brand new media, mark them as ARPE-19 cells with a marker pen, record the date of experiment and the name of the experimenter, and transfer an appropriate amount of pre-prepared media. Take out the culture dish in the incubator, tap it to make the cells slide off, observe whether the cells are flowing under the light, use an optical microscope to observe the dispersion of the cells, and then transfer to the test tube. Put the test tube containing the cells into a high-speed centrifuge for 3 minutes (1000r·min -1 ), and take it out after the time is up. Use an aspirator to suck away the supernatant, add the medium with a pipette gun, and blow up the cells at the bottom, up and down thirty times. Transfer the complete cells after pipetting to a new Petri dish, then perform cross-shaking, and place them in an incubator for cultivation. Incubate for 48 hours at 37°C, 5% CO 2 .

4、细胞冻存4. Cell cryopreservation

当培养皿中的细胞长至80%左右时将其冻存。从冰箱中拿出DMEM培养基和胰蛋白酶,提早安排在37℃水浴锅中预热。戴上新的一次性无菌手套,点击关闭超净台中的紫外灯的按钮,打开排风系统和日光灯,打开酒精灯,含75%酒精擦拭超净台。将约37℃的DMEM培养基、胰蛋白酶进行瓶口灭菌,转移至新的15mltube同样瓶口灭菌。用移液枪加入新的培养基洗去死细胞,然后吸走。再用移液枪移入2ml胰蛋白酶,呈十字摇摆约20次。把培养皿置于培养箱中消化3min,然后取出并拍散细胞,移入5-6mlDMEM培养基,吹打细胞直至均匀,用离心机以1000r·min-1,离心3min。拿出细胞冻存管,标识表记标帜好细胞种类(ARPE-19细胞),冻存日期等信息。拿出冷冻液并用酒精灯灭菌瓶口。拿出离心后的细胞,抽净上清液,移入1.5ml冷冻液,吹打至细胞分散均匀,将细胞移入冻存管,拧紧冻存管瓶口,封口膜包裹灭菌后的冻存管,放于-80℃的冰箱,等待48h,移入液氮罐。Freeze the cells in the dish when they are about 80% full. Take out the DMEM medium and trypsin from the refrigerator, and arrange to preheat it in a 37°C water bath in advance. Put on new disposable sterile gloves, click the button to turn off the ultraviolet lamp in the ultra-clean bench, turn on the exhaust system and fluorescent lamp, turn on the alcohol lamp, and wipe the ultra-clean bench with 75% alcohol. Sterilize the DMEM medium and trypsin at about 37°C, transfer to a new 15ml tube and sterilize the same. Wash off dead cells by adding new medium with a pipette, then aspirate. Then transfer 2ml of trypsin with a pipette gun, and shake about 20 times in a cross shape. Put the petri dish in the incubator for 3min to digest, then take out and beat the cells, transfer into 5-6ml DMEM medium, blow and beat the cells until uniform, centrifuge at 1000r·min -1 for 3min with a centrifuge. Take out the cell freezing tube, and mark the cell type (ARPE-19 cells), freezing date and other information. Take out the cryogen and sterilize the top of the bottle with an alcohol burner. Take out the centrifuged cells, pump out the supernatant, transfer 1.5ml of freezing liquid, pipette until the cells are evenly dispersed, transfer the cells into the cryopreservation tube, tighten the cap of the cryopreservation tube, wrap the sterilized cryopreservation tube with parafilm, Put it in a refrigerator at -80°C, wait for 48 hours, and move it into a liquid nitrogen tank.

MTT法检测千金文武汤对ARPE-19细胞的毒性Toxicity of Qianjin Wenwu Decoction to ARPE-19 cells detected by MTT assay

采用MTT法测定各给药物浓度对细胞的毒性,从而确定最佳给药浓度。MTT method was used to measure the toxicity of each drug concentration to cells, so as to determine the optimal drug concentration.

1、种板1. Seed board

将DMEM培养基,胰酶放到37℃的水浴锅中加热。关闭超净台的紫外灯,打开照明与通风,戴上一次性手套,喷上75%的酒精进行消毒,继续将超净台的台面喷洒75%的酒精进行擦拭,消毒处理。把培养箱中长满ARPE-19细胞的培养基拿出,放到显微镜下观察ARPE-19的生长情况,将长好的ARPE-19细胞拿到超净台上。点燃酒精灯,培养基,胰酶瓶口消毒处置。先用PBS洗去死细胞,用吸引器吸走PBS。往培养皿中加入3ml胰酶,十字摇晃30下,放入培养箱当中3min。拿出培养皿,加入DMEM培养基终止消化,将细胞转移到试管中。放入超高速离心机中离心3min(1000r·min-1)取出试管,吸走上清液,加入培养基吹散底部细胞,取15μl液体放入计数板,在显微镜下计数,按照提前设置好的种板密度开始稀释。把稀释好的细胞悬浮液打入96孔板中,每孔体积200μl。把96孔板放入培养箱中培养18h。Heat the DMEM medium and trypsin in a water bath at 37°C. Turn off the ultraviolet lamp of the ultra-clean table, turn on the lighting and ventilation, put on disposable gloves, spray 75% alcohol for disinfection, and continue to spray 75% alcohol on the surface of the ultra-clean table for wiping and disinfection. Take out the culture medium full of ARPE-19 cells in the incubator, put it under a microscope to observe the growth of ARPE-19, and take the grown ARPE-19 cells to the ultra-clean bench. Light the alcohol lamp, and disinfect the mouth of the medium and trypsin bottles. Wash the dead cells with PBS first, and suck up the PBS with an aspirator. Add 3ml of trypsin to the Petri dish, shake it crosswise for 30 times, and put it in the incubator for 3 minutes. Take out the petri dish, add DMEM medium to stop the digestion, and transfer the cells to the test tube. Centrifuge in an ultra-high-speed centrifuge for 3 minutes (1000r·min -1 ), take out the test tube, suck off the supernatant, add medium to blow off the cells at the bottom, take 15 μl of the liquid into a counting plate, and count under a microscope, according to the settings in advance The seed board density begins to dilute. The diluted cell suspension was poured into a 96-well plate with a volume of 200 μl per well. Put the 96-well plate into the incubator for 18h.

2、考察一定浓度药物对ARPE-19细胞的影响2. To investigate the effect of a certain concentration of drugs on ARPE-19 cells

把96孔板加入千金文武汤提取物,每孔分别加入100μl药物,(每组依次给药10μg,50μg,100μg,200μg,300μg,500μg,1000μg,2000μg)然后用手轻拍孔板周围,再放入培养箱中处理18h。18h之后再加入MTT试剂(5mg·ml-1)20μl,避光保存。具有活性的细胞可以把MTT还原为水不溶性的蓝色结晶甲臜,然后放入培养箱中继续孵育4h。4h后,加入100μl溶解液使甲臜结晶溶解,继续放入培养箱中4h后,用锡纸包好。Add the extract of Qianjin Wenwu Decoction to the 96-well plate, add 100 μl of drug to each well, (each group is given sequentially 10 μg, 50 μg, 100 μg, 200 μg, 300 μg, 500 μg, 1000 μg, 2000 μg) into the incubator for 18 hours. After 18 hours, 20 μl of MTT reagent (5 mg·ml -1 ) was added and stored in the dark. Active cells can reduce MTT to water-insoluble blue crystalline formazan, and then put it into the incubator for further incubation for 4 hours. After 4 hours, add 100 μl of dissolving solution to dissolve the formazan crystals, put them in the incubator for 4 hours, and wrap them with tin foil.

3数据检测3 data detection

将分光光度计打开并设置好参数,检测570nm的吸光度。Turn on the spectrophotometer and set the parameters to detect the absorbance at 570nm.

当APRE-19细胞被给予不同浓度的千金文武汤后,结果如图2所示,500μg组的细胞存活率为84.76%,说明给药500μg(浓度为5μg·μl-1)时无明显毒性,且细胞生长良好。When APRE-19 cells were given different concentrations of Qianjin Wenwu Decoction, the results are shown in Figure 2. The cell survival rate in the 500 μg group was 84.76%, indicating that there was no obvious toxicity when administered with 500 μg (concentration: 5 μg·μl -1 ). And the cells grow well.

细胞造模cell modeling

将DMEM培养基,胰酶放到37℃的水浴锅中加热。用胰蛋白酶消化ARPE-19细胞,放入培养箱中消化3min,时间到后取出观察细胞消化状况,加入3ml培养基,吹打还没消化的细胞,将培养皿中的停止消化的ARPE-19细胞悬液加入试管中,将试管放入离心机,设置好1000r·min-1,时间3min。到时间后将试管取出,吸走上层清液,加入3ml培养基吹起底部细部,然后把细胞种入6孔板中,放置完毕后,再放进37℃,5%CO2培养箱中培养;在每个培养皿中加入含不同浓度的葡萄糖无血清培养基(葡萄糖终浓度为25μmol·L-1、5μmol/L-1、30μmol/L-1、40μmol·L-1、50μmol·L-1)处理72h。显微镜下观察细胞形态,通过造模实验得到最佳的给药浓度,用于药物处理细胞。Heat the DMEM medium and trypsin in a water bath at 37°C. Digest ARPE-19 cells with trypsin, put them in the incubator for 3 minutes, take them out to observe the digestion status of the cells after the time is up, add 3ml medium, blow and beat the cells that have not been digested, and remove the ARPE-19 cells that have stopped digesting in the culture dish Add the suspension into a test tube, put the test tube into a centrifuge, and set it at 1000r·min -1 for 3 minutes. After the time is up, take out the test tube, suck away the supernatant, add 3ml medium to blow up the bottom details, and then plant the cells into a 6-well plate, and then put them in a 37°C, 5% CO 2 incubator for culture ; Serum-free medium containing different concentrations of glucose was added to each culture dish (the final concentration of glucose was 25 μmol L -1 , 5 μmol/L -1 , 30 μmol / L -1 , 40 μmol L -1 , 50 μmol L -1 1 ) Treat for 72 hours. Cell morphology was observed under a microscope, and the optimal dosage concentration was obtained through modeling experiments for drug treatment of cells.

APRE-19细胞分别给予5μmol·L-1和50μmol·L-1的葡萄糖无血清培养基。与5μmol·L-1组相比,50μmol·L-1组细胞呈现显著的纺锤形,细胞间隙变大,融合度降低,表明ARPE-19细胞在葡萄糖浓度为50μmol·L-1时模型指标更明显,故确定50μmol·L-1作为造模的葡萄糖浓度。倒置相差显微镜下观察细胞造模结果见图1,其中,A:给予5μmol·L-1葡萄糖;B:给予50μmol·L-1葡萄糖。APRE-19 cells were given 5 μmol·L -1 and 50 μmol·L -1 glucose serum-free medium, respectively. Compared with the 5 μmol L -1 group, the cells in the 50 μmol L -1 group showed a significant spindle shape, the intercellular space became larger, and the degree of fusion decreased, indicating that the ARPE-19 cells had better model indicators when the glucose concentration was 50 μmol L -1 . Obviously, 50 μmol·L -1 was determined as the glucose concentration for modeling. The results of cell modeling observed under an inverted phase-contrast microscope are shown in Figure 1, in which, A: 5 μmol·L -1 glucose was administered; B: 50 μmol·L -1 glucose was administered.

细胞分组及给药Cell grouping and dosing

将细胞移至6孔板中,生长18h后,观察细胞的生长情况。在每孔中加入细胞造模中确定葡萄糖浓度的无血清培养基处理72h。细胞分为空白组、模型组、低剂量组、中剂量组和高剂量组,空白组、模型组不给予药物,低剂量组给药浓度为0.1μg·μl-1,中剂量组给药浓度为2μg·μl-1,高剂量组给药浓度为5μg·μl-1。给药后培养观察72h。吸取每孔的药物,然后每孔给予裂解液130μl,冷冻过夜。The cells were transferred to a 6-well plate, and after 18 hours of growth, the growth of the cells was observed. Serum-free medium with glucose concentration determined in cell modeling was added to each well for 72 hours. The cells were divided into blank group, model group, low-dose group, middle - dose group and high-dose group. The blank group and the model group were not given drugs. The concentration was 2μg·μl -1 , and the administration concentration of the high dose group was 5μg·μl -1 . After administration, culture and observe for 72 hours. Aspirate the drug in each well, then give 130 μl of lysate to each well, and freeze overnight.

蛋白免疫印迹实验Western blotting

1、提取蛋白质1. Extract protein

准备细胞刮子,PBS缓冲液,用细胞刮子用力的刮六孔板,刮掉粘在六孔板上的蛋白质,每刮完一组用PBS缓冲液冲洗细胞刮子。用移液枪将六孔板中的蛋白质悬液,转移至2ml的tube中。将tube放入冷冻离心机,4℃离心10min,转速13000。用移液枪将离心后的上层清液转移至1.5ml的tube中,将tube放入-20℃保存。13000r·min-1。收集上清液,放入-20℃保存。Prepare the cell scraper, PBS buffer, scrape the six-well plate vigorously with the cell scraper, scrape off the protein sticking to the six-well plate, and rinse the cell scraper with PBS buffer after each scraping group. Transfer the protein suspension in the six-well plate to a 2ml tube with a pipette gun. Put the tube into a refrigerated centrifuge and centrifuge at 4°C for 10 min at a speed of 13,000. Transfer the centrifuged supernatant to a 1.5ml tube with a pipette gun, and store the tube at -20°C. 13000r·min -1 . Collect the supernatant and store it at -20°C.

2、制胶2. Glue making

选取1cm配胶用玻璃板,清洗干净,用夹子夹好后用三蒸水验漏;从冰箱中拿出AA、APS,按照配胶表配好8%和12%的分离胶和浓缩胶(先不加TEMED),震荡混匀,确定玻璃板不漏,倒出三蒸水并用纸把水吸干,分离胶中加入TEMED并震荡混匀,保持充分布满,在确保分离胶高度的前提下,用1ml的移液枪注入到玻璃板中,留出浓缩胶所需空间,再用甲醇填满,左右晃动使胶面平整,静置。待分离胶凝固后(约1h),倒出甲醇,用三蒸水洗三次,用纸吸干,试梳子,确保梳子于玻璃板贴合。浓缩胶加入TEMED并震荡混匀,动作迅速的注入玻璃板,然后迅速的插入梳子,应该避免气泡的产生;静置待浓缩胶完全凝固后拔出梳子,清洗样孔,确保样孔中没有浓缩胶,擦干水待用。配好的胶板若不立即使用,可用锡纸或保鲜膜包好放入4℃冰箱中冷藏。Select a 1cm glass plate for glue mixing, clean it, clamp it with clips, and check for leaks with three-distilled water; take out AA and APS from the refrigerator, and prepare 8% and 12% separating gel and stacking gel according to the glue mixing table ( Do not add TEMED first), shake and mix well, make sure that the glass plate does not leak, pour out triple distilled water and dry the water with paper, add TEMED to the separating gel and shake and mix well to keep it fully covered, on the premise of ensuring the height of the separating gel Next, use a 1ml pipette gun to inject into the glass plate, leaving the space required for the stacking gel, then fill it with methanol, shake it left and right to make the gel surface smooth, and let it stand. After the separation gel is solidified (about 1 hour), pour out the methanol, wash with triple distilled water three times, blot dry with paper, and test the comb to ensure that the comb adheres to the glass plate. Add the concentrated gel to TEMED and oscillate to mix well, quickly pour into the glass plate, and then quickly insert the comb to avoid the generation of air bubbles; wait until the concentrated gel is completely solidified, pull out the comb, and clean the sample well to ensure that there is no concentration in the sample well Glue, wipe off the water and set aside. If the prepared plastic sheet is not used immediately, it can be wrapped in tin foil or plastic wrap and placed in a 4°C refrigerator for refrigeration.

3、电泳3. Electrophoresis

将胶板用夹子夹好并放入电泳槽中,小玻璃板侧朝内;两板之间加入新的1×runningbuffer,没过内侧小玻璃板,周围加入回收的runningbuffer;用10μl的移液枪先在第一个胶孔加入1μlmark,再依次加入样品;电泳,恒流(30mA)跑胶,当蛋白质样品到达凝胶底部1cm时(约1h),关闭电源。Clamp the gel plate with clips and put it into the electrophoresis tank with the side of the small glass plate facing inward; add new 1×running buffer between the two plates, cover the inner small glass plate, and add recovered running buffer around it; pipette with 10μl Add 1 μl mark to the gun first, and then add samples in sequence; electrophoresis, run the gel at a constant current (30mA), and turn off the power when the protein sample reaches the bottom 1cm of the gel (about 1h).

4、转印4. Transfer printing

电泳结束后,准备两张PVDF膜浸泡在适量甲醇中;在合适的容器中倒入transbuffer,依次放入夹子、转印用棉花、PVDF膜。撬开胶板,刮去浓缩胶,划开分离胶四周,迅速将胶放在PVDF膜上,盖上棉花,夹好夹子;将固定夹放入转移罐中,倒入转换缓冲液,并将转移罐放入冰中。开始转印,恒压65V转印1h,恒压35V转印1h。After electrophoresis, prepare two PVDF membranes and soak them in appropriate amount of methanol; pour transbuffer into a suitable container, put in clips, cotton for transfer, and PVDF membrane in turn. Pry open the rubber plate, scrape off the concentrated gel, scratch the surrounding of the separation gel, quickly put the glue on the PVDF membrane, cover with cotton, and clip the clip; put the clip into the transfer tank, pour the conversion buffer, and transfer Place jars in ice. Start transfer printing, transfer with constant voltage 65V for 1h, and transfer with constant voltage 35V for 1h.

5、洗膜,贴抗体5. Wash the membrane and paste the antibody

量取100ml0.05%PBS-T20,再称取5g洗膜用牛奶溶于其中,混合均匀,将转印完的PVDF膜放入牛奶中封闭1h;然后取出PVDF膜用0.05%PBS-T20清洗四次,依次为15min、5min、5min、5min;孵育相应的一抗(抗体比例详见说明书,用含5%w·v-1脱脂奶粉或BSA的PBS-T20缓冲液稀释),摇床上室温下摇晃4h或4℃孵育12h;贴完一抗后,再用0.05%PBS-T20依次清洗15min、5min、5min、5min;贴二抗:加入过氧化酶标记的相应的二抗(使用含2.5%w·v-1脱脂奶粉的PBS-T20缓冲液配制),摇床上室温孵育1h;二抗摇完后取出PVDF膜,用0.05%PBS-T20依次清洗15min、15min、15min。Measure 100ml of 0.05% PBS-T20, then weigh 5g of membrane washing milk and dissolve it in it, mix evenly, put the transferred PVDF membrane into milk to seal for 1 hour; then take out the PVDF membrane and wash it with 0.05% PBS-T20 Four times, followed by 15min, 5min, 5min, 5min; incubate the corresponding primary antibody (see the instructions for the ratio of the antibody, diluted with PBS-T20 buffer containing 5% w·v -1 skimmed milk powder or BSA), shake at room temperature Shake for 4 hours or incubate at 4°C for 12 hours; after the primary antibody is attached, wash with 0.05% PBS-T20 for 15 minutes, 5 minutes, 5 minutes, and 5 minutes; %w·v -1 skimmed milk powder in PBS-T20 buffer), incubated on a shaker at room temperature for 1h; after the secondary antibody was shaken, the PVDF membrane was removed and washed with 0.05% PBS-T20 for 15min, 15min, and 15min in sequence.

6、显像6. Imaging

将洗好的转印膜放到暗室里,各取A液和B液1ml,用移液枪混合均匀;准备显影剂和清水,打开红外灯关闭日光灯,注意不能曝光,剪取胶片;用镊子取出膜后,用纸把膜上的混合液体吸走,将膜放在混合物中,用移液枪冲洗;将漂洗好的膜放进夹板中塑料薄膜内,用纸去除气泡并固定,观察是否有荧光;若荧光较明显,剪好的膜片被放在胶片上,关闭夹板片刻后,立即取出胶片(注意不能错位,以防显出的条带模糊;若荧光不明显或者未观察到荧光,则关上夹板置于暗处一段时间后再进行后续操作(关闭夹子防止膜变干);在显影液中从最底部放入薄膜,并将其完全浸泡,当看到出现条带较清晰的斑点时,即可取出胶片放入水中清洗,洗净后再放入定影液中进行定影,如图3所示。Put the washed transfer film in a dark room, take 1ml of liquid A and liquid B, and mix evenly with a pipette; prepare developer and water, turn on the infrared light and turn off the fluorescent light, pay attention not to expose, cut the film; use tweezers After taking out the membrane, use paper to absorb the mixed liquid on the membrane, put the membrane in the mixture, and rinse it with a pipette gun; put the rinsed membrane into the plastic film in the splint, use paper to remove air bubbles and fix it, and observe whether There is fluorescence; if the fluorescence is obvious, the cut membrane is placed on the film, and after closing the splint for a while, take out the film immediately (be careful not to misplace it, so as to prevent the blurred bands; if the fluorescence is not obvious or no fluorescence is observed , then close the splint and place it in a dark place for a period of time before performing subsequent operations (close the clamp to prevent the film from drying); put the film in the developer from the bottom and soak it completely, when you see clearer bands When there are spots, you can take out the film and put it in water for cleaning, and then put it into the fixer for fixing after cleaning, as shown in Figure 3.

ARPE-19细胞被给予药物后细胞E-cad、α-SMA和COL-I蛋白的表达情况结果如图4(###:P<0.001vs空白组,***:P<0.001**:P<0.01vs模型组)所示,由图3和图4可知,与空白组相比,模型组E-cad的表达水平明显降低,COL-I、α-SMA的表达水平明显升高,表明模型建立。当给予各浓度药物后,药物以剂量依赖性方式下调α-SMA与COL-I的表达,上调E-cad的表达。这些结果表明千金文武汤能干预高糖诱导ARPE-19细胞的纤维化进程。The results of the expression of E-cad, α-SMA and COL-I proteins in ARPE-19 cells after being given drugs are shown in Figure 4 (###: P<0.001vs blank group, ***: P<0.001**: P<0.01vs model group), as can be seen from Figure 3 and Figure 4, compared with the blank group, the expression level of E-cad in the model group was significantly reduced, and the expression levels of COL-I and α-SMA were significantly increased, indicating that Model building. After administration of various concentrations of the drug, the drug down-regulated the expression of α-SMA and COL-I, and up-regulated the expression of E-cad in a dose-dependent manner. These results indicated that Qianjin Wenwu Decoction could interfere with the fibrosis process of ARPE-19 cells induced by high glucose.

本发明实验结果表明,高糖诱导后,与正常组比较,模型组细胞明显变长呈纺锤形,且E-cad蛋白表达下调,α-SMA和COL-I蛋白表达上调;给药后,与模型组比较,以剂量依赖性方式上调E-cad蛋白表达,下调α-SMA和COL-I蛋白表达。The experimental results of the present invention show that after induction by high glucose, compared with the normal group, the cells in the model group are obviously elongated and spindle-shaped, and the expression of E-cad protein is down-regulated, and the expression of α-SMA and COL-I protein is up-regulated; Compared with the model group, the expression of E-cad protein was up-regulated in a dose-dependent manner, and the protein expression of α-SMA and COL-I was down-regulated.

朝医方“千金文武汤”能够干预高糖诱导视网膜色素上皮细胞ARPE-19的纤维化进程。The Korean medical prescription "Qianjin Wenwu Decoction" can interfere with the fibrosis process of ARPE-19 in retinal pigment epithelial cells induced by high glucose.

以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。The above is only a preferred embodiment of the present invention, it should be pointed out that, for those of ordinary skill in the art, without departing from the principle of the present invention, some improvements and modifications can also be made, and these improvements and modifications can also be made. It should be regarded as the protection scope of the present invention.

Claims (5)

1. application of the civil and military soup of a thousand pieces of gold in the drug that retinal pigment epithelium ARPE-19 fibrosis is intervened in preparation.
2. application of the civil and military soup of a thousand pieces of gold in the drug that preparation inhibits retinal pigment epithelium ARPE-19 fibrosis.
3. the civil and military soup of a thousand pieces of gold answering in the drug that preparation inhibits high glucose induction retinal pigment epithelium ARPE-19 fibrosis With.
4. described in any item applications according to claim 1~3, which is characterized in that the standby raw material processed of the civil and military soup of a thousand pieces of gold It is made of pueraria lobata, radix scutellariae, rhizoma ligustici, Chinese yam, Schisandra chinensis, campanulaceae, cimicifugae foetidae, the root of Dahurain angelica and Radix Ophiopogonis.
5. application according to claim 4, which is characterized in that the standby raw material processed of the civil and military soup of a thousand pieces of gold by pueraria lobata 10g, Radix scutellariae 10g, rhizoma ligustici 10g, Chinese yam 10g, Schisandra chinensis 5g, campanulaceae 5g, cimicifugae foetidae 5g, root of Dahurain angelica 5g and Radix Ophiopogonis 5g composition.
CN201910942490.XA 2019-09-30 2019-09-30 Application of the civil and military soup of a thousand pieces of gold in the drug that retinal pigment epithelium ARPE-19 fibrosis is intervened in preparation Pending CN110478430A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910942490.XA CN110478430A (en) 2019-09-30 2019-09-30 Application of the civil and military soup of a thousand pieces of gold in the drug that retinal pigment epithelium ARPE-19 fibrosis is intervened in preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910942490.XA CN110478430A (en) 2019-09-30 2019-09-30 Application of the civil and military soup of a thousand pieces of gold in the drug that retinal pigment epithelium ARPE-19 fibrosis is intervened in preparation

Publications (1)

Publication Number Publication Date
CN110478430A true CN110478430A (en) 2019-11-22

Family

ID=68544755

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910942490.XA Pending CN110478430A (en) 2019-09-30 2019-09-30 Application of the civil and military soup of a thousand pieces of gold in the drug that retinal pigment epithelium ARPE-19 fibrosis is intervened in preparation

Country Status (1)

Country Link
CN (1) CN110478430A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053204A1 (en) * 1999-03-09 2000-09-14 China Pharmaceutical University A pharmaceutical composition for treating angiocardiopathy and the method of producing thereof
CN108743795A (en) * 2018-08-30 2018-11-06 延吉朝耀生物科技有限公司 A kind of prevention diabetic nephropathy towards medicament extract and its preparation method and application

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053204A1 (en) * 1999-03-09 2000-09-14 China Pharmaceutical University A pharmaceutical composition for treating angiocardiopathy and the method of producing thereof
CN108743795A (en) * 2018-08-30 2018-11-06 延吉朝耀生物科技有限公司 A kind of prevention diabetic nephropathy towards medicament extract and its preparation method and application

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
谷李影等: "下调miR-25对高糖诱导视网膜色素上皮细胞系ARPE-19细胞Smad7和VEGF表达的影响", 《临床和实验医学杂志》 *

Similar Documents

Publication Publication Date Title
CN111218420B (en) Extraction method of bitter gourd exosomes and application of bitter gourd exosomes in preparation of antitumor drugs
CN106539821A (en) A kind of stem cell excretion body preparation and its preparation method and application
CN107881197A (en) One kind immortalizes cow rumen epithelial cell line and its construction method
CN116234561B (en) Pharmaceutical composition for preventing and treating respiratory diseases in winter
CN101560268A (en) Cs-4 fermentation mycelium polysaccharide and preparation method and applications thereof
CN110982868A (en) Co-culture method for improving triterpene content of ganoderma lucidum and application
CN118853531A (en) A kind of ginseng tuber exosome-like vesicle and its preparation method and application
CN114917240B (en) Eucommia ulmoides composition and its application in treating glomerular diseases
CN111549000B (en) Recombinant adipose-derived stem cell for over-expression of Hpgds, preparation method and application thereof
CN110478430A (en) Application of the civil and military soup of a thousand pieces of gold in the drug that retinal pigment epithelium ARPE-19 fibrosis is intervened in preparation
CN116855559A (en) Preparation method and application of Chlamydomonas nivalis oligosaccharide for regulating skin microecology
CN116178509A (en) Preparation method and application of bifidobacterium surface protein
CN110452948A (en) Deer heart protein hydrolyzate and its preparation method and application
CN108113993A (en) A kind of applications of cucurbitacin D in glioma cell activity inhibitor is prepared
CN115105523B (en) Oxidative damage protection of turnip neutral polysaccharide BRNP on cells
CN106755101A (en) A kind of is the method for iPS cells by the reprogramming of equinovarus Urine in Patients cast-off cells
CN100355427C (en) Method for extracting substance with cell respiration stimulating activity from pig blood
CN109536567B (en) Composition, reagent for detecting cell activity containing the composition, and method for detecting cell activity
CN106420770A (en) Autophagy revulsive for diabetic vascular complication treatment and application in medicine
CN115975906A (en) Cultivation method of mantle cells of Triangle sail mussel
CN119157882B (en) Application of SRT2104 in preparation of medicament for treating bronchial asthma
CN119606945B (en) Application of 4-methylesculetin, a potential active ingredient of xiasangju, in the preparation of drugs for the prevention and treatment of diabetes
CN114848691B (en) Use of the extract of ethyl acetate of C. japonica in the preparation of drugs for reducing lipid and losing weight
CN108721357A (en) Application of the erigeron breviscapus extracts in preparing veterinary drug
CN110302194A (en) A kind of compound preparation with anti-inflammatory and skin barrier protective effect Cineole combination with glucocorticoids

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20191122

RJ01 Rejection of invention patent application after publication